Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease and its diagnosis has classically been based on clinical symptoms. Recently, a biological rather than a syndromic definition of the disease has been proposed that is based on biomarkers that reflect neuropathological changes. In A...
Main Authors: | Marta Milà-Alomà, Marc Suárez-Calvet, José Luís Molinuevo |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-12-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756286419888819 |
Similar Items
-
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
by: Oriol Grau-Rivera, et al.
Published: (2021-02-01) -
The meaning of blood and cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease
by: Julita Szarpak, et al.
Published: (2020-09-01) -
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
by: Alain D. Dekker, et al.
Published: (2017-01-01) -
Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
by: Carolina A. Magalhães, et al.
Published: (2015-12-01) -
Cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease
by: Jun WANG, et al.
Published: (2014-04-01)